• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Surging Revenue And Late-Stage Trial Progress Might Change The Case For Investing In Mesoblast (ASX:MSB)

    Simply Wall St·08/28/2026 16:25:32
    Listen to the news
    • Mesoblast Limited has reported full-year 2026 results showing revenue of US$120.25 million versus US$17.2 million a year earlier, with its net loss reduced to US$57.5 million from US$102.14 million and loss per share almost halved.
    • Alongside RYONCIL’s first full year of commercial sales, Mesoblast has completed patient treatment in a pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, underscoring its dual focus on near-term revenue and late-stage pipeline assets.
    • Now, we’ll examine how this sharp revenue increase and progress in the chronic low back pain program affect Mesoblast’s investment narrative.

    AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Mesoblast Investment Narrative Recap

    To own Mesoblast today, you need to believe that RYONCIL can keep scaling from its first full year of sales while late stage assets like rexlemestrocel L move closer to potential approval. The sharp lift in FY26 revenue and narrower loss help the cash burn story, but the most important near term catalyst remains future pivotal data and regulatory progress. The biggest risk is that commercial uptake or trial outcomes fall short, keeping Mesoblast dependent on external funding.

    The completion of patient treatment in the MSB DR004 Phase 3 trial for chronic low back pain ties directly into that catalyst. With 350 patients treated and RMAT status secured, Mesoblast now has a clear path toward a key data readout in 2027 that could reshape its revenue mix and reduce reliance on a single rare disease indication if outcomes are supportive.

    Yet beneath the stronger revenue print, investors should also be aware that...

    Read the full narrative on Mesoblast (it's free!)

    Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.

    Uncover how Mesoblast's forecasts yield a A$3.83 fair value, a 59% upside to its current price.

    Exploring Other Perspectives

    ASX:MSB 1-Year Stock Price Chart
    ASX:MSB 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already cautious, assuming Mesoblast might need US$480.8 million of revenue and US$162.9 million of earnings by 2029 to justify their targets, and they focused heavily on the risk that continued operating cash outflows and rising commercial costs could force more capital raises if sales do not accelerate as hoped after this latest update.

    Explore 6 other fair value estimates on Mesoblast - why the stock might be worth as much as 95% more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Mesoblast research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.

    Interested In Other Possibilities?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.